Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/236164
Share/Export:
logo share SHARE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Title

Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma

AuthorsPaiva, Bruno; Puig, Noemi; Cedena, Maria-Teresa; Rosiñol, Laura; Cordón, Lourdes; Vidriales, Maria Belén; Burgos, Leire; Flores-Montero, Juan; Sanoja-Flores, Luzalba; López-Anglada, Lucía; Maldonado, Roberto; Cruz, Javier de la; Gutiérrez, Norma C.; Calasanz, Mª Jose; Martín-Ramos, María Luisa; García-Sanz, Ramón; Martínez-López, Joaquín; Oriol, Albert; Blanchard, María Jesús; Ríos, Rafael; Martín, Jesús; Martínez-Martínez, Rafael; Sureda, Anna; Hernandez, Miguel T.; Rubia, Javier de la; Krsnik, Isabel; Moraleda, José María; Palomera, Luis; Bargay, Joan
Issue Date10-Mar-2020
PublisherAmerican Society of Clinical Oncology
CitationJournal of Clinical Oncology 38(8): 784-792 (2020)
Abstract[Purpose] Assessing measurable residual disease (MRD) has become standard with many tumors, but the clinical meaning of MRD in multiple myeloma (MM) remains uncertain, particularly when assessed by next-generation flow (NGF) cytometry. Thus, we aimed to determine the applicability and sensitivity of the flow MRD-negative criterion defined by the International Myeloma Working Group (IMWG).
[Patients and methods] In the PETHEMA/GEM2012MENOS65 trial, 458 patients with newly diagnosed MM had longitudinal assessment of MRD after six induction cycles with bortezomib, lenalidomide, and dexamethasone (VRD), autologous transplantation, and two consolidation courses with VRD. MRD was assessed in 1,100 bone marrow samples from 397 patients; the 61 patients without MRD data discontinued treatment during induction and were considered MRD positive for intent-to-treat analysis. The median limit of detection achieved by NGF was 2.9 × 10−6. Patients received maintenance (lenalidomide ± ixazomib) according to the companion PETHEMA/GEM2014MAIN trial.
[Results] Overall, 205 (45%) of 458 patients had undetectable MRD after consolidation, and only 14 of them (7%) have experienced progression thus far; seven of these 14 displayed extraosseous plasmacytomas at diagnosis and/or relapse. Using time-dependent analysis, patients with undetectable MRD had an 82% reduction in the risk of progression or death (hazard ratio, 0.18; 95% CI, 0.11 to 0.30; P < .001) and an 88% reduction in the risk of death (hazard ratio, 0.12; 95% CI, 0.05 to 0.29; P < .001). Timing of undetectable MRD (after induction v intensification) had no impact on patient survival. Attaining undetectable MRD overcame poor prognostic features at diagnosis, including high-risk cytogenetics. By contrast, patients with Revised International Staging System III status and positive MRD had dismal progression-free and overall survivals (median, 14 and 17 months, respectively). Maintenance increased the rate of undetectable MRD by 17%.
[Conclusions] The IMWG flow MRD-negative response criterion is highly applicable and sensitive to evaluate treatment efficacy in MM.
Publisher version (URL)http://doi.org/10.1200/JCO.19.01231
URIhttp://hdl.handle.net/10261/236164
Identifiersdoi: 10.1200/JCO.19.01231
issn: 0732-183X
e-issn: 1527-7755
Appears in Collections:(IBIS) Artículos

Files in This Item:
File Description SizeFormat
Multiple_Myeloma.pdf1,39 MBAdobe PDFThumbnail
View/Open
Show full item record
Review this work

Page view(s)

51
checked on Jan 17, 2022

Download(s)

200
checked on Jan 17, 2022

Google ScholarTM

Check


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.